2.64

8.65% -0.25

After Hours: 2.64

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $2.64, with a volume of 1.03M. It is down -8.65% in the last 24 hours and down -32.82% over the past month. Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Previous Close:

$2.89

Open:

$2.87

24h Volume:

1.03M

Relative Volume:

1.35

Market Cap:

$98.57M

Revenue:

Net Income/Loss:

$-144.01M

P/E Ratio:

-0.6584

EPS:

-4.01

Net Cash Flow:

$-113.02M

1W Performance:

-20.96%

1M Performance:

-32.82%

6M Performance:

-63.79%

1Y Performance:

-85.18%

1-Day Range:

$2.58

$2.9599

1-Week Range:

$2.58

$3.34

52-Week Range:

$2.58

$18.50

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1189)

Industry

Biotechnology (682)

Phone

(650) 980-9099

Address

900 MIDDLEFIELD ROAD, REDWOOD CITY

Employee

107

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	2.64	98.57M	0	-144.01M	-113.02M	-4.01
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

08:27 AM

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

08:27 AM

08:26 AM

Biomea Fusion reports inducement grant under Nasdaq listing rule - TipRanks

08:26 AM

Mar 02, 2025

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 02, 2025

Feb 28, 2025

Biomea Fusion Says Franco Valle Resigns As CFO -February 28, 2025 at 04:16 pm EST - Marketscreener.com

Feb 28, 2025

Biomea Fusion to Unveil New Icovamenib Data at the 18th - GlobeNewswire

Feb 28, 2025

Feb 27, 2025

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times

Feb 27, 2025

Can This Diabetes Drug Work Long After You Stop Taking It? Biomea's Surprising Clinical Results - StockTitan

Feb 27, 2025

Feb 26, 2025